Here are six articles published by Becker's Hospital Review in the past week that highlight device issues or recalls, blood shortages and the fight against high drug prices, among other issues.
1. Fujifilm to pull 4 older duodenoscope models from use
Fujifilm Medical Systems plans to remove four legacy duodenoscope models from clinical use "based on the limited number currently in use," according to a Food and Drug Administration safety alert issued Jan. 13.
2. Washington, D.C.-area hospitals desperate for blood donations ahead of inauguration
Hospitals in the Washington, D.C., area have voiced an urgent call to increase collections of blood supplies as they prepare for potential emergencies during the upcoming presidential inauguration weekend, reports WTOP.
3. Lannett will be first drugmaker to go bankrupt amid price scrutiny, short seller predicts
Andrew Left, a well-known short seller at Citron Research, predicts generic drug firm Lannett will be the first drugmaker to go bankrupt amid ongoing drug pricing scrutiny, according to a report released Tuesday.
4. FDA safety alert: LIFEPAK 1000 defibrillator shuts down unexpectedly during treatment
The FDA issued a safety alert Jan. 14 regarding Physio-Control's LIFEPAK 1000 defibrillator after reported incidents of the device shutting down suddenly during treatment.
5. Drugmakers want new FDA chief to have medical background
Pharmaceutical executives are calling on President-elect Donald Trump to appoint someone with a medical background to serve as chief of the FDA, and ensure the agency continues evaluating the effectiveness of new therapies.
6. Bernie Sanders: Democrats don't have the guts to fight pharma
Vermont Sen. Bernie Sanders (I) on Thursday criticized 13 Senate Democrats for voting against a measure he proposed to control drug costs, saying they lacked the "guts" to stand up to the drug industry.
More articles on supply chain:
Supply chain tip of the week: How to manage excessive drug price hikes
Drug shortage spurs FDA to allow use of topical gel approved in Europe
Novartis to consider more US investments amid Trump tax cuts